Literature DB >> 29529278

Testing Positive on a Multigene Panel Does Not Suffice to Determine Disease Risks.

Hormuzd A Katki1, Mark H Greene1, Maria Isabel Achatz1.   

Abstract

Mesh：

Year:  2018        PMID： 29529278      PMCID： PMC6279260          DOI： 10.1093/jnci/djy008

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  12 in total

1.  Inference from a multiplicative model of joint genetic effects for [corrected] ovarian cancer risk.

Authors:  Sholom Wacholder; Summer S Han; Clarice R Weinberg
Journal:  J Natl Cancer Inst       Date:  2010-12-17       Impact factor: 13.506

2.  Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families.

Authors:  Hormuzd A Katki; Mitchell H Gail; Mark H Greene
Journal:  Lancet Oncol       Date:  2007-12       Impact factor: 41.316

3.  Multigene Testing for Hereditary Cancer: When, Why, and How.

Authors:  Kenneth Offit
Journal:  J Natl Compr Canc Netw       Date:  2017-05       Impact factor: 11.908

4.  Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing.

Authors:  Huma Q Rana; Rebecca Gelman; Holly LaDuca; Rachel McFarland; Emily Dalton; Jennifer Thompson; Virginia Speare; Jill S Dolinsky; Elizabeth C Chao; Judy E Garber
Journal:  J Natl Cancer Inst       Date:  2018-08-01       Impact factor: 13.506

5.  The prevalence of DICER1 pathogenic variation in population databases.

Authors:  Jung Kim; Amanda Field; Kris Ann P Schultz; D Ashley Hill; Douglas R Stewart
Journal:  Int J Cancer       Date:  2017-08-21       Impact factor: 7.396

6.  Cancer risk among the HIV-infected elderly in the United States.

Authors:  Elizabeth L Yanik; Hormuzd A Katki; Eric A Engels
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

7.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.

Authors:  Anita Villani; Ari Shore; Jonathan D Wasserman; Derek Stephens; Raymond H Kim; Harriet Druker; Bailey Gallinger; Anne Naumer; Wendy Kohlmann; Ana Novokmet; Uri Tabori; Marta Tijerin; Mary-Louise C Greer; Jonathan L Finlay; Joshua D Schiffman; David Malkin
Journal:  Lancet Oncol       Date:  2016-08-05       Impact factor: 41.316

8.  Meta-analysis of BRCA1 and BRCA2 penetrance.

Authors:  Sining Chen; Giovanni Parmigiani
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

9.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Authors:  Karoline B Kuchenbaecker; John L Hopper; Daniel R Barnes; Kelly-Anne Phillips; Thea M Mooij; Marie-José Roos-Blom; Sarah Jervis; Flora E van Leeuwen; Roger L Milne; Nadine Andrieu; David E Goldgar; Mary Beth Terry; Matti A Rookus; Douglas F Easton; Antonis C Antoniou; Lesley McGuffog; D Gareth Evans; Daniel Barrowdale; Debra Frost; Julian Adlard; Kai-Ren Ong; Louise Izatt; Marc Tischkowitz; Ros Eeles; Rosemarie Davidson; Shirley Hodgson; Steve Ellis; Catherine Nogues; Christine Lasset; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker; Laurence Faivre; Pascaline Berthet; Maartje J Hooning; Lizet E van der Kolk; Carolien M Kets; Muriel A Adank; Esther M John; Wendy K Chung; Irene L Andrulis; Melissa Southey; Mary B Daly; Saundra S Buys; Ana Osorio; Christoph Engel; Karin Kast; Rita K Schmutzler; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Michael L Friedlander; Sue-Anne McLachlan; Eva Machackova; Lenka Foretova; Yen Y Tan; Christian F Singer; Edith Olah; Anne-Marie Gerdes; Brita Arver; Håkan Olsson
Journal:  JAMA       Date:  2017-06-20       Impact factor: 56.272

10.  Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening.

Authors:  A Smith; A Moran; M C Boyd; M Bulman; A Shenton; L Smith; R Iddenden; E R Woodward; F Lalloo; E R Maher; D G R Evans
Journal:  J Med Genet       Date:  2006-11-01       Impact factor: 6.318
View more
  1 in total

1.  The impact of the number of tests presented and a provider recommendation on decisions about genetic testing for cancer risk.

Authors:  Marci L B Schwartz; William M P Klein; Lori A H Erby; Christy H Smith; Debra L Roter
Journal:  Patient Educ Couns       Date:  2020-09-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.